ID 原文 译文
1283 可能的相互作用 Potential interactions
1284 联合用药禁忌 Contraindication in combined medication
1286 与 CYP3A 代谢的药物 (例如他汀类、他克莫司等免疫抑制剂、伏立康唑)可导致合用药物的血浆浓度升高，导致利伐沙班AUC增加153%，阿托伐他汀AUC增加5.9倍，咪达唑仑AUC增加13倍，要注意临床症状及TDM的监测； When combined with drugs associated with CYP3A metabolism (e.g., statins, immunosuppressors such as tacrolimus, voriconazole), the plasma concentration of the combined drug may increase; leading to 153%, 5.9 folds, 13 folds increase of the AUC of rivaroxaban, atrovastatin, midazolam, respectively. Pay attention to clinical symptoms and apply the TDM.
1287 严禁与胺碘酮（致命性心律失常）、喹硫平（严重昏迷）、辛伐他汀（横纹肌溶解）等联合使用； Combined use with amiodarone (fatal arrhythmia), quetiapine (severe coma), simvastatin (rhabdomyolysis) is prohibited.
1288 达芦那韦/考比司他 darunavir/ cobicistat
1289 与主要经由CYP3A和/或CYP2D6代谢的药品联合用药时可导致此类药品血浆浓度升高；相互作用药物参考洛匹那韦/利托那韦； When combined with drugs associated with CYP3A and/or CYP2D6 metabolism, the plasma concentration of the combined drugs may increase.
1290 参考洛匹那韦/利托那韦； See lopinavir/ ritonavir.
1292 与CYP3A4及UGT1A9底物、抑制剂和诱导剂之间存在药物相互作用 It interacts with CYP3A4, UGT1A9 substrates, inhibitors, and inducers.
1294 ①茶碱可使法匹拉韦生物利用度上升； Theophyllinum increases the bioavailability of fapilavir.
1295 ②可使乙酰氨基酚生物利用度上升到1.79倍； It increases the bioavailability of acetaminophen by 1.79 folds.